Derek Archila
Stock Analyst at Wells Fargo
(4.35)
# 356
Out of 5,131 analysts
229
Total ratings
53.9%
Success rate
16.75%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Overweight | $109 → $78 | $55.95 | +39.41% | 2 | Feb 17, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $88 → $98 | $75.25 | +30.23% | 3 | Feb 13, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $107 → $101 | $101.10 | -0.10% | 13 | Feb 11, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $26 → $29 | $27.90 | +3.94% | 3 | Feb 3, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $30 → $29 | $15.60 | +85.90% | 8 | Jan 29, 2026 | |
| ARGX argenx SE | Maintains: Overweight | $1,264 → $1,317 | $821.96 | +60.23% | 15 | Jan 20, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $106 → $114 | $37.24 | +206.12% | 3 | Jan 20, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $129 → $145 | $98.07 | +47.85% | 7 | Jan 20, 2026 | |
| ASND Ascendis Pharma | Maintains: Overweight | $322 → $330 | $216.61 | +52.35% | 16 | Jan 20, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $29 → $26 | $21.70 | +19.82% | 14 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $479 → $376 | $314.40 | +19.59% | 2 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $30 | $17.92 | +67.41% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $14 | $13.97 | +0.21% | 6 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $39 | $26.54 | +46.95% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $33 | $7.26 | +354.55% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $116 | $82.34 | +40.88% | 10 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $25 | $9.99 | +150.25% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $27 | $4.89 | +452.15% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $18 → $28 | $27.50 | +1.82% | 5 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.65 | +28.76% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $53.07 | +52.63% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $43.92 | -31.69% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $6.30 | -20.63% | 12 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $1.89 | +429.10% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.89 | +11.87% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $22.97 | +65.43% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $30 | $16.16 | +85.64% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $2.80 | -28.57% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $2.39 | +109.21% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $3.90 | +284.62% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $22.60 | -38.05% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $25.75 | +74.76% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $3.43 | +483.09% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.17 | +191.73% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $33.90 | +469.32% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $86.11 | -52.39% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $14.74 | +985.48% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $20.96 | +186.26% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $6.09 | +376.19% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.15 | +4,247.83% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $20.10 | +153.73% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $14.54 | +505.23% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $21.76 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $33.98 | - | 2 | Aug 3, 2017 |
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $109 → $78
Current: $55.95
Upside: +39.41%
BridgeBio Pharma
Feb 13, 2026
Maintains: Overweight
Price Target: $88 → $98
Current: $75.25
Upside: +30.23%
Incyte
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $107 → $101
Current: $101.10
Upside: -0.10%
Viridian Therapeutics
Feb 3, 2026
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $27.90
Upside: +3.94%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $30 → $29
Current: $15.60
Upside: +85.90%
argenx SE
Jan 20, 2026
Maintains: Overweight
Price Target: $1,264 → $1,317
Current: $821.96
Upside: +60.23%
Soleno Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $106 → $114
Current: $37.24
Upside: +206.12%
Rhythm Pharmaceuticals
Jan 20, 2026
Maintains: Overweight
Price Target: $129 → $145
Current: $98.07
Upside: +47.85%
Ascendis Pharma
Jan 20, 2026
Maintains: Overweight
Price Target: $322 → $330
Current: $216.61
Upside: +52.35%
Apellis Pharmaceuticals
Jan 20, 2026
Maintains: Overweight
Price Target: $29 → $26
Current: $21.70
Upside: +19.82%
Jan 20, 2026
Maintains: Equal-Weight
Price Target: $479 → $376
Current: $314.40
Upside: +19.59%
Jan 8, 2026
Maintains: Overweight
Price Target: $22 → $30
Current: $17.92
Upside: +67.41%
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $14
Current: $13.97
Upside: +0.21%
Jan 6, 2026
Maintains: Overweight
Price Target: $17 → $39
Current: $26.54
Upside: +46.95%
Dec 16, 2025
Maintains: Overweight
Price Target: $31 → $33
Current: $7.26
Upside: +354.55%
Dec 9, 2025
Maintains: Overweight
Price Target: $69 → $116
Current: $82.34
Upside: +40.88%
Dec 8, 2025
Maintains: Overweight
Price Target: $19 → $25
Current: $9.99
Upside: +150.25%
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $4.89
Upside: +452.15%
Nov 14, 2025
Upgrades: Overweight
Price Target: $18 → $28
Current: $27.50
Upside: +1.82%
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $11.65
Upside: +28.76%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $53.07
Upside: +52.63%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $43.92
Upside: -31.69%
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.30
Upside: -20.63%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $1.89
Upside: +429.10%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.89
Upside: +11.87%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $22.97
Upside: +65.43%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $40 → $30
Current: $16.16
Upside: +85.64%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.80
Upside: -28.57%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $2.39
Upside: +109.21%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $3.90
Upside: +284.62%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $22.60
Upside: -38.05%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $25.75
Upside: +74.76%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $3.43
Upside: +483.09%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $6.17
Upside: +191.73%
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $33.90
Upside: +469.32%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $86.11
Upside: -52.39%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $14.74
Upside: +985.48%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $20.96
Upside: +186.26%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $6.09
Upside: +376.19%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.15
Upside: +4,247.83%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $20.10
Upside: +153.73%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $14.54
Upside: +505.23%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $21.76
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $33.98
Upside: -